Analysis of Reverse Transcriptase Gene Mutations in the Hepatitis B Virus at a University Hospital in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Most mutations in the reverse transcriptase (RT) gene of the hepatitis B virus (HBV) are related to resistance to antiviral agents. Cross-sectional studies on the mutations of this gene are rare. Thus, we analyzed the mutation patterns of RT genes and their bio- chemical parameters. Methods: From 2009 to 2012, 301 blood specimens from patients with chronic hepatitis B at Daegu Catholic University Medical Center were retrospectively analyzed for the RT gene sequence of HBV, ALT, hepatitis B e antigen (HBeAg), and HBV DNA. The mutation patterns of the RT gene were compared with the biochemical parameters. Results: Of the 301 patients, 100 (33.2%) had no RT gene mutations. The remaining showed the following mutation patterns: rtM204I/V (50.2%), rtL180M (39.2%), and rtA181T/V (19.6%). Combined mutations were found in 146 cases (48.5%). Of these, the combination of amino acid changes at rt180+rt204 (49.3%) was most frequently detected, followed by rt181+rt236 (11.0%) and rt173+rt180+rt204 (9.6%). In the mutated group, HBV DNA and HBeAg positive rates were significantly higher ( P <0.05 for both). Pheno- typic analysis showed that lamivudine resistance was most frequently detected (34.6%), followed by adefovir resistance (15.6%). Multidrug resistance was detected in 48 cases (15.9%). The adefovir-resistant group had a higher proportion of cases with HBV loads greater than 2,000 IU/mL. Conclusions: We found correlations between the mutation status of the RT domain and biochemical parameters such as HBV DNA and HBeAg positive rate. The presence of RT gene mutations could therefore be utilized to predict clinical status.
Abstract
Background: Most mutations in the reverse transcriptase (RT) gene of the hepatitis B virus (HBV) are related to resistance to antiviral agents. Cross-sectional studies on the mutations of this gene are rare. Thus, we analyzed the mutation patterns of RT genes and their bio- chemical parameters. Methods: From 2009 to 2012, 301 blood specimens from patients with chronic hepatitis B at Daegu Catholic University Medical Center were retrospectively analyzed for the RT gene sequence of HBV, ALT, hepatitis B e antigen (HBeAg), and HBV DNA. The mutation patterns of the RT gene were compared with the biochemical parameters. Results: Of the 301 patients, 100 (33.2%) had no RT gene mutations. The remaining showed the following mutation patterns: rtM204I/V (50.2%), rtL180M (39.2%), and rtA181T/V (19.6%). Combined mutations were found in 146 cases (48.5%). Of these, the combination of amino acid changes at rt180+rt204 (49.3%) was most frequently detected, followed by rt181+rt236 (11.0%) and rt173+rt180+rt204 (9.6%). In the mutated group, HBV DNA and HBeAg positive rates were significantly higher ( P <0.05 for both). Pheno- typic analysis showed that lamivudine resistance was most frequently detected (34.6%), followed by adefovir resistance (15.6%). Multidrug resistance was detected in 48 cases (15.9%). The adefovir-resistant group had a higher proportion of cases with HBV loads greater than 2,000 IU/mL. Conclusions: We found correlations between the mutation status of the RT domain and biochemical parameters such as HBV DNA and HBeAg positive rate. The presence of RT gene mutations could therefore be utilized to predict clinical status.
참고문헌 (19)
- The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV)2009-Health Examination, "Korea Centers for Disease Control and Prevention", Korea Centers for Disease Control and Prevention, ~ (2010)
- Franco E, "Hepatitis B: Epidemiology and prevention in developing countries", World J Hepatol, 4, pp.74~80 (2012)
- Hussain M, "Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B", Viral Hepat, 6, pp.183~194 (1999)
- Shaw T, "HBV drug resistance: mechanisms, detection and interpretation", J Hepatol, 44, pp.593~606 (2006)
- Yim HJ, "Hepatitis B virus genetic diversity and mutant", Korean J Hepatol, 14, pp.446~464 (2008)
- Huang ZM, "YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines", World J Gastroenterol, 11, pp.867~870 (2005)
- Zhao J, "The natural YMDD mutations of hepatitis B virus in Western China", Scand J Infect Dis, 44, pp.44~47 (2012)
- Tan YW, "YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study", Braz J Infect Dis, 16, pp.250~255 (2012)
- Orlando R, "Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report", Infection, 36, pp.472~474 (2008)
- Wang F, "Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and addon nucleoside", nucleotide analogues, 2009, pp.31, 360~366
- Bartholomeusz A, "Hepatitis B virus mutations associated with antiviral therapy", J Med Virol, 78(1), pp.52~55 (2006)
- 문재현, "라미부딘 내성 만성 B형간염 환자에서 아데포비어 단독치료의 효과와 아데포비어에 대한 유전자형 내성의 발생 양상", Clinical and Molecular Hepatology, 14(4), pp.503~512 (2008), 대한간학회
- Locarnini S, "Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV", Antivir Ther, 12(3), pp.15~23 (2007)
- Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: Management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- Yuen MF, "Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B", Am J Gastroenterol, 99, pp.2032~2037 (2004)
- Mommeja-Marin H, "Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection:analysis and review of the literature", Hepatology, 37, pp.1309~1319 (2003)
- Alagiozian-Angelova V, "Clinical significance of serum HBeAg and HBV-DNA-specific values of virus replication in chronic hepatitis-B virus infection", Folia Med (Plovdiv), 40, pp.34~41 (1998)
- Enomoto M, "Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences", J Med Virol, 79, pp.1664~1670 (2007)
- Ono SK, "The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance", J Clin Invest, 107, pp.449~455 (2001)